Information Provided By:
Fly News Breaks for May 18, 2017
ELGX
May 18, 2017 | 09:04 EDT
Oppenheimer analyst Steven Lichtman downgraded Endologix to Perform and lowered his price target for the shares to $5.50 from $10. The downgrade follows the company's announcement that it willseek U.S. approval of the Nellix EVAS System by conducting a confirmatory clinical study. BTIG and Stifel this morning also downgraded Endologix.
News For ELGX From the Last 2 Days
There are no results for your query ELGX